up home page bottom

French German version Spanish version Italian version

header image

Call For Scientific Inquiry Into The HPV Vaccine Used in The UK

Executive Director of the Alliance for Natural Health, Robert Verkerk, stated: “Young girls in the UK—as well as their parents and guardians—deserve to have the full facts on the risks and benefits of this vaccine to help them make properly informed choices. The NHS position is that the vaccine is safe, but the facts would suggest otherwise. Presently, there are no adequate data available on the comparative risks of Cervarix and Gardasil. Neither is there adequate information on the factors which may predispose certain individuals to serious adverse reactions, nor about the duration and effectiveness of immunity following single and multiple vaccinations. It is in the public interest—and of utmost urgency—that these key questions are answered by an independent scientific review panel and are made public.”

Lancet Study Indicates Cervarix HPV Vaccine Effective Against The Five Most Common Cervical Cancer-Causing Viruses

A study, published in Tuesday’s issue of The Lancet, said that as well as protecting against the two most common virus types, the GlaxoSmithKline Plc’s Cervarix vaccine also provides protection against the next three most common cancer-causing virus types. GlaxoSmithKline Plc’s is Europe’s biggest drug company.

Volunteer Researchers Raise Questions about HPV Vaccine Efficacy

International Coalition of Advocates for the People’s first educational advocacy effort has been a success. Seven women who became international advocates wrote a paper about HPV vaccines to educate all necessary parties in Europe. This paper has been distributed throughout Europe and to select individuals in the United States. Presently, thirteen German scientists from the Robert Koch Institute are questioning the effectiveness of these vaccines. They are also asking for evidence now from the Standing Committee based on the scientists’ views.

Glaxo wins European contract for Cervarix

GlaxoSmithKline has won another European contract for the cervical cancer vaccine Cervarix. The Dutch government selected Cervarix for a new program to vaccinate all girls aged 12 with a catch-up program for girls aged 13 to 16 in the second half of 2009. In the first year some 350,000 Dutch girls will get the jab.

Cervarix, GSK’s Cervical Cancer Vaccine, Wins Tender For Dutch National Immunisation Programme

GlaxoSmithKline’s (GSK) cervical cancer vaccine, Cervarix, was today confirmed by the Netherlands Vaccine Institute (NVI) as the cervical cancer vaccine for the Dutch National Immunisation Programme (NIP).

Private